BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px
Document › Details

Kinaxo Biotechnologies GmbH. (4/16/08). "Press Release: Kinaxo Biotechnologies Enters Agreement with Takeda". Martinsried.

Organisation Organisation Kinaxo Biotechnologies GmbH
  Group Evotec (Group)
Products Product Cellular Target Profiling technology (Kinaxo)
  Product 2 mass spectrometry (MS)
Index term Index term Takeda–Kinaxo: KinaTor™ technology, 200804– use of KinaTor by Takeda San Diego Inc
Person Person Jenne, Andreas (Blackfield 2012– CEO + founder before Kinaxo 200603– CEO + founder + NascaCell IP GmbH CEO + co-founder)

KINAXO Biotechnologies announced today that it has entered an agreement with Takeda San Diego, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Osaka, Japan. Under the agreement, KINAXO will make its KinaTor™ technology available to Takeda researchers involved in drug discovery, preclinical research and clinical development. KINAXO's Cellular Target Profiling utilizes proprietary chemical proteomics technologies combined with state-of-the-art mass spectrometry to identify and characterize a drug candidate's native molecular targets in cell lines and tissue samples. This service enables pharmaceutical and biotechnology companies to make more informed decisions on which drug candidates to progress into advanced pre-clinical or clinical development. "We consider this agreement with Takeda, the leading R&D-oriented pharmaceutical company of Japan, to be a major progress in the world-wide expansion of our business", said Dr. Andreas Jenne, the chief executive officer of KINAXO. "We continue to demonstrate the validation of the KinaTor™ technology by providing services to leading pharmaceutical and biotechnology companies, including Johnson& Johnson, Bayer-Schering, Takeda and UCB Pharma."

KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. We support pharmaceutical and biotechnology companies in their development and optimization of drug leads. Amongst others KINAXO has ongoing collaborations with UCB Pharma and Johnson & Johnson. KINAXO offers its clients a comprehensive chemical-proteomics platform - known as KinaTor™ - that identifies and characterizes the interaction of small molecule inhibitors with their cellular protein targets. Tailored to protein kinases, the KinaTor™ technology supports more informed lead candidate selection. Licensing agreements with GPC Biotech AG and the Max Planck Society provides KINAXO Biotechnologies GmbH with exclusive worldwide rights to use the KinaTor™ technology in contract research activities. KINAXO is financed by European investors BioM, High-Tech Gründerfonds, KfW, Max Planck Society, and Mountain Partners.

Record changed: 2016-03-19


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Evotec (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px